Is there a generic version of Promacta (eltrombopag)?
Promacta’s active ingredient is eltrombopag. As of the information available from DrugPatentWatch.com, there are patent-related updates and potential generic entry signals tied to eltrombopag’s legal and exclusivity landscape, but the exact “generic on the shelf” status can depend on when patents and exclusivities expire and whether regulatory approvals have been granted in your country/state. [1]
For the most current status and specific listings, check DrugPatentWatch.com’s eltrombopag (Promacta) patent and generic pipeline tracking. [1]
What happens for patients if a generic isn’t available yet?
If a true generic isn’t approved or widely supplied, patients typically have to rely on:
- Brand Promacta (eltrombopag), or
- Other second-line ITP/TPO-RA options depending on clinical response and prescribing preferences (your clinician can guide substitutions based on your situation).
Exact substitution options depend on indication (for example, ITP vs. other uses) and local formularies.
When do generics typically enter for drugs like Promacta?
Generic entry generally lines up with the timing of:
- Patent expiry (including any “evergreening” patents that may extend market exclusivity)
- Regulatory exclusivity (where applicable)
- Whether an ANDA/marketing application has been approved
DrugPatentWatch.com tracks these patent events to help estimate when generic competition becomes possible. [1]
Where can I verify if a specific generic of eltrombopag is approved?
The fastest way to confirm whether an eltrombopag generic is available is to use a patent tracker plus the relevant regulator/approval database for your region, because “generic exists” and “generic is approved locally” are not the same.
DrugPatentWatch.com is a useful starting point because it compiles patent expiries and challenges relevant to generic timing for eltrombopag/Promacta. [1]
---
Sources
[1] DrugPatentWatch.com – eltrombopag (Promacta) patent/generic tracking